Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a share - Earnings Preview

Reuters
03-07
<a href="https://laohu8.com/S/KALV">Kalvista Pharmaceuticals Inc</a> <kalv.oq> expected to post a loss of 87 cents a share - Earnings Preview </kalv.oq>
  • Kalvista Pharmaceuticals Inc KALV.OQ KALV.O is expected to show no change in quarterly revenue when it reports results on March 10 (estimated) for the period ending January 31 2025

  • ​LSEG's mean analyst estimate for Kalvista Pharmaceuticals Inc is for a loss of 87 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Kalvista Pharmaceuticals Inc is $28.00​, above​ its last closing price of $11.98. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Oct. 31 2024

-0.90

-0.91

-0.91

Met

-0.2

Jul. 31 2024

-0.92

-0.91

-0.87

Beat

4.8

Apr. 30 2024

-0.84

-0.73

-1.02

Missed

-39.4​

Jan. 31 2024

-0.77

-0.77

-0.84

Missed

-9.5

​​Oct. 31 2023

-0.77

-0.79

-0.80

Missed

-1.7

Jul. 31 2023

-0.84

-0.86

-0.74

Beat

13.8​

Apr. 30 2023

-0.83

-0.94

-0.77

Beat

17.9

Jan. 31 2023

-0.92

-0.98

-0.75

Beat

23.9

This summary was machine generated March 7 at 13:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10